Phenoconversion Reporting: How Labs Show Drug-Modified Phenotypes

Phenoconversion reporting means telling the prescriber that a patient's genotype-predicted phenotype may no longer match how the patient metabolizes a drug, because a co-medication or another non-genetic factor has changed enzyme activity. A sound report keeps the genotype result fixed, shows the drug-adjusted phenotype separately, names the interacting medication, states the date of the medication list it relied on, and flags when that list changes. This article sets out what that looks like for a clinical laboratory, where the calculation is well defined, where it is not, and how to deliver it without adding to alert fatigue.

SignalPGx

Keep PGx Reports Current

SignalPGx combines genotype data, medication histories, and clinical evidence in physician-reviewed reports for laboratories.

Explore SignalPGx

TL;DR

Phenoconversion is the mismatch between a genotype-based prediction and true metabolic capacity caused by non-genetic factors, most often a drug that inhibits or induces the enzyme.
A static PGx report can become outdated the day a patient starts a strong CYP inhibitor, so the report should separate the genotype phenotype from the medication-adjusted phenotype.
CYP2D6 has the most mature method: CPIC-style activity score adjustment using inhibitor strength, but dose, timing and washout still need clinical judgment.
Alert fatigue is a design problem. Context-aware, workflow-integrated decision support works; interruptive pop-ups that ignore the full clinical picture do not.
Labs that treat reporting as a living process, with medication history inputs, medical director review and an audit trail, are best placed to handle this.

What phenoconversion is, and why a genotype report misses it
What a phenoconversion-aware report should contain
How the CYP2D6 adjustment works
Why a static report is not enough
Reporting without alert fatigue
Our perspective: reporting is a process, not a document
Building a lab workflow for phenoconversion reporting
How SignalPGx supports this
FAQ
Sources

What phenoconversion is, and why a genotype report misses it

Pharmacogenetic reports typically assign one of four phenotypes for drug-metabolizing enzymes: ultrarapid, normal, intermediate or poor metabolizer. For CYP2D6, these come from an activity score, where a score of 0 is a poor metabolizer, values above 0 and below 1.25 are intermediate, 1.25 to 2.25 normal, and above 2.25 ultrarapid.

That assignment describes the germline. It cannot see what the patient takes on Tuesday. Phenoconversion is the gap: a patient whose DNA says normal metabolizer can behave like a poor metabolizer while on a strong inhibitor. In practice this is a drug-drug-gene interaction, and it is why a report built only from genotype can be out of date as soon as a medication changes.

The effect is not rare. In a 2024 study of CYP2C19-genotyped healthy volunteers, phenoconversion occurred in over 80% of participants given interacting drugs, with the proportion varying by genotype group. For a lab, the practical implication is that the clinical phenotype and the genetic phenotype are two different results, and a report that collapses them into one will mislead in at least some patients.

What a phenoconversion-aware report should contain

The most common failure is not a wrong calculation but an unclear one. A prescriber who reads "Poor Metabolizer" cannot tell whether it came from DNA or from paroxetine. We recommend the following elements, each in its own labeled place.

Genotype layer

Star allele diplotype using standardized PharmVar nomenclature, with the predicted phenotype and activity score. Laboratory guidance recommends clear interpretations of phenotype predictions and standardized nomenclature.
Stated limitations. Without phasing, multiple diplotype combinations can produce the same phenotype, and the report should say so rather than imply certainty.
For CYP2D6, the copy number method and its limits. See our CYP2D6 copy number guide for US labs for what to store and disclose.

Medication layer

The interacting drug, its inhibitor or inducer class, and the source of that classification.
The date and origin of the medication list (order requisition, EHR feed, pharmacist interview).
Whether the adjusted phenotype is a calculation, an estimate or an unverified possibility.

Interpretation layer

The genotype-based recommendation and the medication-adjusted recommendation side by side.
What would change the result: stopping the inhibitor, a dose change, or a washout period.
Medical director review status and sign-out date.

This mirrors a broader point from the clinical decision support literature: reports should go beyond a result and include clinically actionable medication recommendations so providers can use the data immediately.

How the CYP2D6 adjustment works

CYP2D6 is the gene where phenoconversion is best characterized. The FDA classifies CYP2D6 inhibitors as strong, moderate or weak according to their effect on exposure to sensitive index substrates. A strong inhibitor raises substrate AUC at least 5-fold. Strong inhibitors such as paroxetine, fluoxetine and bupropion, and moderate inhibitors such as duloxetine and sertraline, can convert a genotypic normal metabolizer into a phenotypic poor or intermediate metabolizer respectively.

The published approach multiplies the genotype-based activity score by an inhibitor factor: 0 for a strong inhibitor, 0.5 for a moderate one and 1 for none. A worked example:

Genotype	Activity score	Co-medication	Inhibitor factor	Adjusted score	Resulting phenotype
1/1	2.0	None	1	2.0	Normal metabolizer
1/1	2.0	Moderate inhibitor	0.5	1.0	Intermediate metabolizer
1/1	2.0	Strong inhibitor	0	0	Poor metabolizer
1/4	1.0	Strong inhibitor	0	0	Poor metabolizer

The arithmetic is the easy part. A tutorial on integrating this into practice notes that phenoconversion is dynamic and depends on the half-lives of both the inhibitor and the substrate, so dose dependency and washout periods matter and the status is not simply yes or no. A lab report should therefore present the adjusted phenotype as a prediction tied to a dated medication list, not as a permanent property of the patient.

Where the inputs are unreliable

Inhibitor classification is itself inconsistent in practice. We examined this in our analysis of CYP2D6 inhibitor labels, which found 62% concordance between labs and clinicians. If your lab and the prescriber's pharmacy system disagree on whether a drug is a moderate or strong inhibitor, the same patient will receive different advice depending on who looks. Fix the classification source and cite it in the report.

Beyond CYP2D6

The same logic applies to CYP2C19 and other enzymes, but the methods are less standardized, and inducers, inflammation and other non-genetic modifiers add further variability. Where no consensus factor exists, we advise reporting the interaction as a qualitative flag with a recommendation for clinical review rather than inventing a numeric adjustment.

Why a static report is not enough

Clinical teams are encouraged to work in collaborative care models for this reason: a static PGx report cannot reflect a medication profile that changes after the sample is processed. The most useful reports reflect the interplay of genes with current drug-drug, drug-disease and drug-age interactions.

For a laboratory, that has three consequences.

Version the report. A reissued report with a new medication snapshot should supersede, not overwrite, the original, and both should stay in the audit trail.
Time-stamp the medication inputs. A reader should see at a glance how current the adjustment is.
Plan for re-evaluation. Decide in advance which events trigger a re-run: a new strong or moderate inhibitor, discontinuation of one, or a guideline update.

Codeine is the classic illustration. A genotypic normal metabolizer on a strong CYP2D6 inhibitor may get little analgesia, while the genotype-only report would say the standard dose is appropriate. Our codeine and CYP2D6 prescribing guide walks through the genotype side of that decision.

Reporting without alert fatigue

The second question readers raise is how to deliver phenoconversion information without worsening alert fatigue. It is a legitimate concern: phenoconversion produces conditional logic, and conditional logic is exactly what tends to become a pop-up.

Experts attribute the problem mainly to interruptive alerts that fire without regard to the patient's full clinical context, with override rates above 90%. The remedy they describe is context-aware decision support integrated into existing workflows rather than a hard stop in front of the clinician. For teams thinking through how generative tools might fit that kind of workflow, this overview of a generative AI clinical decision support system is a relevant starting point.

A design that holds up:

Fire only on a change that matters. Alert when a new inhibitor alters the phenotype for a drug the patient actually takes or is about to be prescribed, not when any interacting drug appears on a list.
Make the first screen short. One line: gene, genotype phenotype, adjusted phenotype, drug responsible.
Keep detail one click away. Activity score math, inhibitor strength and references belong in the expanded view.
Use tiers. Reserve interruptive alerts for high-consequence drug-gene pairs and send everything else as passive, in-context information.
Close the loop. Track overrides, and treat a high override rate on a specific rule as a defect in the rule.

Getting structured results into the EHR is the precondition. Our guidance on mapping one gene-drug pair in FHIR first applies directly: store the genotype phenotype, the adjusted phenotype and the medication snapshot as separate discrete fields, so downstream rules can act on them without parsing a PDF.

Our perspective: reporting is a process, not a document

We build reporting infrastructure for laboratories, and the pattern we see repeatedly is that phenoconversion exposes the weakest assumption in PGx reporting: that a result is final once it is signed. The genotype is final. The clinical interpretation is not.

Our perspective: reporting is a process, not a document — overview diagram

That is why we designed the platform around a few principles. Medication histories are inputs alongside genotype data, so the interpretation reflects what the patient is taking. Medication intelligence simulation lets a lab and its clinicians evaluate how a drug-response or risk picture would change under a different medication scenario. Living reanalysis updates recommendations as clinical guidelines evolve, so the report does not freeze on the guideline version in force at sign-out. And the medical director stays in control: every interpretation is physician-reviewed with an audit trail, because an adjusted phenotype is a clinical judgment that a lab should own.

We would also say plainly what automation should not do. It should not hide uncertainty. Where a washout period is unknown, a dose is unrecorded or the medication list is old, the report should say so. A confident number built on a stale list is worse than an honest flag.

— Tarek

Building a lab workflow for phenoconversion reporting

A practical sequence for a lab that wants to add this capability:

Define scope. Start with CYP2D6, where the method is established, and with drugs where the clinical consequence is clear. Expand once the workflow is stable. Our CPIC implementation checklist is a good frame for sequencing.
Choose a single inhibitor classification source and record its version in every report.
Decide how medication data arrives. Requisition fields, HL7/FHIR feeds from the EHR, or a reviewed pharmacist input. Each has different accuracy and timeliness.
Set the report language for adjusted results: genotype phenotype, adjusted phenotype, evidence basis, confidence and review date.
Write the re-evaluation rules, including which medication changes trigger a re-run and who approves the reissued report.
Validate with real cases. Run historical reports with known co-medications through the logic and have the medical director review the discordances.
Monitor. Track reissue rates, prescriber questions and alert overrides.

One caution on evidence. Interpretation also varies between providers: a CPIC conference presentation compared how commercial testing companies' genotype-to-phenotype translations differed from CPIC guidelines, including for CYP2D6 and CYP2C19. If translation tables drift, adjusted phenotypes drift with them, which is why version control of the evidence base belongs in the design from day one.

How SignalPGx supports this

If your lab wants to offer phenoconversion-aware reports under its own brand, our white-label PGx reporting combines genotype data, medication histories and evidence from multiple sources into physician-reviewed reports, with HL7/FHIR integration, audit trails and HIPAA and GDPR compliance. Labs typically deploy within 5 to 7 days. For teams that need to design the workflow first, we also offer Discovery & Strategy from $7,000 one-off per project, followed by System Design and Deployment & Integration.

FAQ

What is phenoconversion in pharmacogenomics?

It is the mismatch between the metabolism predicted from a patient's genotype and the patient's actual capacity, caused by non-genetic factors such as interacting drugs. The genes have not changed, but the enzyme activity has. A normal metabolizer on a strong inhibitor can behave like a poor metabolizer.

Which drugs are affected by CYP2D6?

CYP2D6 is linked to over 70 medications, including many antidepressants, antipsychotics, opioids such as codeine and beta blockers. It is also the enzyme most susceptible to inhibition, so its drug list matters on both sides: substrates and inhibitors.

What is a pharmacogenetic report?

It is a clinical document that interprets genetic test results to guide drug selection and dosing, using CPIC guidelines and FDA-labeled pharmacogenomic biomarkers. A good one shows the diplotype, phenotype and activity score, states its limitations and gives actionable recommendations.

How do we reduce alert fatigue from PGx alerts?

Avoid interruptive alerts that ignore clinical context, which have been associated with override rates above 90%. Fire only when a change alters a phenotype for a relevant drug, keep the first view to one line, and track overrides as a signal that a rule needs repair.